title: Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic Fibrosis.
abstract: BACKGROUND
  Chronic lung disease is the leading cause of death in patients with Cystic Fibrosis (CF) and is often treated with bronchodilators. It is not known whether long-term tiotropium bromide treatment may have a positive impact on lung function.
  
  
  METHODS
  This retrospective cohort study estimated annual lung function decline utilizing longitudinal data for forced expiratory volume in 1 s (FEV1).
  
  
  RESULTS
  A total of 160 adult patients with CF were analyzed. The subjects treated for 24 months with tiotropium bromide had a significantly slower decline of mean annual change of FEV1 (treated: -0.3±4.0%; control: -2.3±5.0%; p = 0.0130). In patients with FEV1 ≥70% predicted, long-term tiotropium bromide treatment was associated with greater improvements in annual lung function decline (FEV1 ≥70% predicted: treated: +0.5±4.7%; control: -4.0±6.3%; p = 0.0132; FEV1 50-69% predicted: treated: -0.5±4.4%; control: -0.8±3.8%; p = 0.7142; FEV1 ≤49% predicted: treated: -0.6±3.4%; control: -2.4±4.8%; p = 0.0898).
  
  
  CONCLUSIONS
  This study suggests that long-term tiotropium bromide treatment may be associated with reduced annual decline of FEV1 in patients with CF, particularly in adults with a mild degree of severity.
authors.affiliation: Department of Pediatric Pneumology and Immunology, Cystic Fibrosis Center / Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
authors.forename: Claudia
authors.initials: C
authors.lastname: Brandt
authors.affiliation: Department of Pediatric Pneumology and Immunology, Cystic Fibrosis Center / Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
authors.forename: Anja
authors.initials: A
authors.lastname: Thronicke
authors.affiliation: Department of Pediatric Pneumology and Immunology, Cystic Fibrosis Center / Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
authors.forename: Jobst F
authors.initials: JF
authors.lastname: Roehmel
authors.affiliation: Biostatistics Unit, Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Krannich
authors.affiliation: Department of Pediatric Pneumology and Immunology, Cystic Fibrosis Center / Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
authors.forename: Doris
authors.initials: D
authors.lastname: Staab
authors.affiliation: Department of Pediatric Pneumology and Immunology, Cystic Fibrosis Center / Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
authors.forename: Carsten
authors.initials: C
authors.lastname: Schwarz
mesh_terms: D000328:Adult; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008168:Lung / Q000503:physiopathology*; D008297:Male; D000069447:Tiotropium Bromide / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D001993:Bronchodilator Agents; D000069447:Tiotropium Bromide